What is Regeneron Pharmaceuticals, Inc. (REGN) DCF Fair Value and Intrinsic Value in 2026?

Regeneron Pharmaceuticals, Inc. (REGN) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Regeneron Pharmaceuticals, Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector (Biotechnology) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Regeneron Pharmaceuticals, Inc.'s financial health rating and Piotroski F-Score?

Regeneron Pharmaceuticals, Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Regeneron Pharmaceuticals, Inc. (REGN) for quarterly SEC filing thesis breaks?

LocalAlpha audits Regeneron Pharmaceuticals, Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksREGN

REGN

Regeneron Pharmaceuticals, Inc.Healthcare / BiotechnologyINTACT

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Share Price

$783.31

52W: $541 - $859.34

DCF Fair Value

$965.73

+18.9%

Thesis Hub

P/E (TTM)

19.4x

ROIC

24.8%

Operating Margin

33.1%

FCF Yield

3.8%

Debt / Equity

0.09x

Piotroski Score

8/9

Altman Z-Score

3.35

Market Cap

$80.6B

Price vs. Intrinsic Value Corridor

Modest Value ($783.31 vs $965.73 DCF)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$965.73

MOS Buy Target (-25%)

$724.30

Valuation Overlays: DCF Fair Value ($965.73) 25% MOS Buy Target ($724.30) Revised Graham ($1232.60) Graham Number ($535.91)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$783.31

DCF Fair Value

$965.96

+18.9%

Starting Free Cash Flow ($M)$3,065M

$100M$3,065M (Reported)$50,000M

Stage 1 Growth (Years 1-5)16.5%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)-$5,300M (Net Cash)

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$37.7B

PV of Terminal Value

$54.6B

Implied Enterprise Value

$92.3B

Implied Equity Value

$97.6B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$3,571	$4,160	$4,846	$5,646	$6,577	$6,873	$7,183	$7,506	$7,844	$8,197
Present Value (PV)	$3,276	$3,501	$3,742	$4,000	$4,275	$4,098	$3,929	$3,767	$3,611	$3,462

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-46.2% Premium

$535.91

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $40.38BVPS: $316.11

Revised Graham Formula+36.5% MoS

$1232.60

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings3.7% Yield

$28.83 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $2.9BYield: 3.7%

Reverse DCF: Market Growth Expectation

FAIR BARRIER

9.0% CAGR (Next 10 Yrs)

At the current price of $783.31, the market is assuming the business will compound Free Cash Flow at 9.0% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil REGN with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Regeneron Pharmaceuticals, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 33.1% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track REGN & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Regeneron Pharmaceuticals, Inc. (REGN) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Regeneron Pharmaceuticals, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Regeneron Pharmaceuticals, Inc. has an estimated DCF intrinsic fair value of $965.73 per share compared to its current market price of $783.31. This represents an estimated 18.9% margin of safety (trading below fair value). Additionally, its classic Benjamin Graham Number stands at $535.91.